NAAA
PTGX icon

New Age Alpha Advisors’s Protagonist Therapeutics PTGX Stock Holding History

New Age Alpha Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$285K Sell
2,706
-78
-3% -$6.91K 0.01% 579
2025
Q4 		$243K Buy
+2,784
New +$228K 0.01% 576

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

New Age Alpha Advisors's PTGX Position: Q1 2026 in Review

New Age Alpha Advisors reduced its Protagonist Therapeutics (PTGX) stake by 2.8% in Q1 2026, selling an estimated $6.91K and leaving 2,706 shares worth $285K. The position accounts for 0.01% of the portfolio, ranked #579.

New Age Alpha Advisors first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • New Age Alpha Advisors held 2,706 shares of Protagonist Therapeutics worth $285K as of Q1 2026.
  • New Age Alpha Advisors sold 78 Protagonist Therapeutics shares in Q1 2026, an estimated $6.91K.
  • Protagonist Therapeutics made up 0.01% of New Age Alpha Advisors's portfolio in Q1 2026, its #579 holding.
  • New Age Alpha Advisors first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on New Age Alpha Advisors's 13F filing for Q1 2026, filed 11 May 2026.